Lysosomal Therapeutics

Lysosomal Therapeutics Inc. (LTI) is dedicated to innovative small-molecule research and development in the field of neurodegeneration, yielding new treatment options for patients with severe neurological diseases. Our strategy leverages the clinically-validated link between lysosome-based genetic disorders and neurodegenerative diseases to establish a unique and effective molecular platform for novel drug discovery. LTI’s lead program targets Gaucher-related neurodegeneration, Parkinson’s disease and other synucleinopathies.
Cambridge, US
Lysosomal Therapeutics was founded in 2014 and is headquartered in Cambridge, US

Key People/Management at Lysosomal Therapeutics

Kees Been

Kees Been

Founder, President and CEO
Daniel Geffken

Daniel Geffken

Paula Ragan

Paula Ragan

Chief Business Officer
Dimitri Krainc

Dimitri Krainc

Scientific Founder, Chairman of the Scientific Advisory Board
Renato Skerlj

Renato Skerlj

Vice President of Drug Discovery and Preclinical Development
Joseph Mazzulli

Joseph Mazzulli

Scientific Founder

Lysosomal Therapeutics Office Locations

Lysosomal Therapeutics has an office in Cambridge
Cambridge, US (HQ)
19 Blackstone Street

Lysosomal Therapeutics Financials and Metrics

Summary Metrics

Founding Date


Total Funding

$24.8 m

Latest funding size

$20 m

Time since last funding

almost 3 years


Lysosomal Therapeutics's latest funding round in February 2015 was reported to be $20 m. In total, Lysosomal Therapeutics has raised $24.8 m

Lysosomal Therapeutics's Web-traffic and Trends

Lysosomal Therapeutics Company Life and Culture

You may also be interested in